Sign in
ALMS Stock Price, Chart, Stats & News
Alumis Inc.
Save
Alumis Inc. (ALMS) does not currently pay a dividend.
3.51B
Market cap
–
Current P/E
–
Forward P/E
ALMS chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 96.40% |
Operating margin | -1837.44% |
Pretax margin | -1047.34% |
Net margin | -1011.75% |
Effective tax rate | 3.40% |
ROA | -59.07% |
ROE | -72.65% |
D/E | 0.12x |
Interest coverage ratio | – |
ALMS valuation
P/E | – |
P/S | 126.98x |
P/B | 8.62x |
P/CF | -7.03x |
P/FCF | -8.25x |
P/OCF | -7.03x |
PEG | -0.48x |
EV multiple | -7.50x |
About
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction.
Similar securities
Based on sector and market capitalization
Report issue